MET and neoplasm: Dacomitinib, an EGFR inhibitor, reduces tumor viability and self-renewal in EGFR-amplified GBM, although its effectiveness is influenced by the PTEN status,383,384 Despite their initial promise, c-MET inhibitors such as onartuzumab and rilotumumab have failed to significantly improve survival outcomes.